Form 4: Olema Pharmaceuticals Director Walmsley Reports Stock Sales

Director Graham G. Walmsley reports the sale of Olema Pharmaceuticals (OLMA) common stock held indirectly through Logos Opportunities Fund I LP and Logos Opportunities Fund II LP.

Summary

• Graham G. Walmsley, a director of Olema Pharmaceuticals, reported the sale of common stock on June 4, 2024.
• The sales were conducted indirectly through Logos Opportunities Fund I LP and Logos Opportunities Fund II LP.
• 700,000 shares were sold at a price of $14.85.
• 475,000 shares were sold at a price of $14.85.
• Following the transactions, Walmsley indirectly owns 700,761 shares through Logos Fund I and 708,114 shares through Logos Fund II.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the document only reports stock sales, such insider activity can sometimes raise concerns among investors.

Negatives

• A director selling a significant number of shares could be interpreted negatively by the market.

Risks

• The market may react negatively to the director's stock sales, potentially impacting the share price.

Industry Context

Insider trading activity is always closely watched in the pharmaceutical industry, as it can provide insights into the perceived prospects of a company and its stock.

Stakeholder Impact

• Shareholders may react to the news of the director's stock sales.

Key Dates